Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Initial experience with paclitaxel-coated stents.
Grube E, Büllesfeld L. Grube E, et al. Among authors: bullesfeld l. J Interv Cardiol. 2002 Dec;15(6):471-5. doi: 10.1111/j.1540-8183.2002.tb01091.x. J Interv Cardiol. 2002. PMID: 12476650 Review.
Drug eluting stents: initial experiences.
Grube E, Gerckens U, Müller R, Büllesfeld L. Grube E, et al. Among authors: bullesfeld l. Z Kardiol. 2002;91 Suppl 3:44-8. doi: 10.1007/s00392-002-1309-x. Z Kardiol. 2002. PMID: 12641014
Self-expanding Transcatheter vs Surgical Aortic Valve Replacement in Intermediate-Risk Patients: 5-Year Outcomes of the SURTAVI Randomized Clinical Trial.
Van Mieghem NM, Deeb GM, Søndergaard L, Grube E, Windecker S, Gada H, Mumtaz M, Olsen PS, Heiser JC, Merhi W, Kleiman NS, Chetcuti SJ, Gleason TG, Lee JS, Cheng W, Makkar RR, Crestanello J, George B, George I, Kodali S, Yakubov SJ, Serruys PW, Lange R, Piazza N, Williams MR, Oh JK, Adams DH, Li S, Reardon MJ; SURTAVI Trial Investigators. Van Mieghem NM, et al. JAMA Cardiol. 2022 Oct 1;7(10):1000-1008. doi: 10.1001/jamacardio.2022.2695. JAMA Cardiol. 2022. PMID: 36001335 Free PMC article. Clinical Trial.
Impact of stent overlap on long-term clinical outcomes in patients treated with newer-generation drug-eluting stents.
O'Sullivan CJ, Stefanini GG, Räber L, Heg D, Taniwaki M, Kalesan B, Pilgrim T, Zanchin T, Moschovitis A, Büllesfeld L, Khattab AA, Meier B, Wenaweser P, Jüni P, Windecker S. O'Sullivan CJ, et al. Among authors: bullesfeld l. EuroIntervention. 2014 Jan 22;9(9):1076-84. doi: 10.4244/EIJV9I9A182. EuroIntervention. 2014. PMID: 24064474 Free article. Clinical Trial.
Clinical outcome and predictors for adverse events after transcatheter aortic valve implantation with the use of different devices and access routes.
Wenaweser P, Pilgrim T, Roth N, Kadner A, Stortecky S, Kalesan B, Meuli F, Büllesfeld L, Khattab AA, Huber C, Eberle B, Erdös G, Meier B, Jüni P, Carrel T, Windecker S. Wenaweser P, et al. Among authors: bullesfeld l. Am Heart J. 2011 Jun;161(6):1114-24. doi: 10.1016/j.ahj.2011.01.025. Epub 2011 May 11. Am Heart J. 2011. PMID: 21641358
Long-term comparison of everolimus- and sirolimus-eluting stents in patients with acute coronary syndromes.
Kalesan B, Stefanini GG, Räber L, Schmutz M, Baumgartner S, Hitz S, Baldinger SH, Pilgrim T, Moschovitis A, Wenaweser P, Büllesfeld L, Khattab AA, Meier B, Jüni P, Windecker S. Kalesan B, et al. Among authors: bullesfeld l. JACC Cardiovasc Interv. 2012 Feb;5(2):145-54. doi: 10.1016/j.jcin.2011.11.005. JACC Cardiovasc Interv. 2012. PMID: 22361598 Free article.
15 results